CD274 and head and neck squamous cell carcinoma: EXTREME regimen (cisplatin or carboplatin plus 5-fluoruracil plus cetuximab) remains the standard of care for patients with HNSCC not expressing PD-L1 and patients with contraindications to anti-programmed death-1 (PD-1) inhibitors [8].